Karnofsky Performance Status (KPS)
Assessment of functional status and quality of life in oncology patients.
Interpretation and Clinical Decisions in Oncology
The Karnofsky Performance Status (KPS) is the oldest and one of the most important clinical assessment scales in oncology. Designed to objectively quantify the performance status and general condition of a cancer patient, this prognostic tool is essential in therapeutic decision-making. It allows oncologists to accurately assess the patient's functional capacity to tolerate heavy and aggressive treatments, such as chemotherapy, radiotherapy, or surgery. By measuring the degree of autonomy and quality of life, the Karnofsky score guides healthcare professionals between indicating active curative treatment and directing towards exclusive palliative care, thereby minimizing the risks of severe toxicity.
Why is the Karnofsky Score Crucial?
Choosing a cancer treatment (chemotherapy, immunotherapy, or major surgery) does not depend solely on the tumor stage. The physiological state of the human body is equally determining. The Karnofsky score plays a central role in this decision-making process:
- Vital Prognosis: A high KPS score is directly correlated with better Overall Survival and a better response to treatments.
- Toxicity Assessment: Patients with a low index have a statistically much higher risk of developing severe or fatal chemotherapy-related complications.
- Transition to Palliative Care: A rapid and progressive decline in the score often indicates that aggressive curative treatments should be stopped in favor of exclusive comfort care.
Oncological Decision Thresholds
- KPS ≥ 70%: The patient is generally considered fit to receive full-dose standard chemotherapy protocols.
- KPS < 60%: Aggressive anticancer treatments are often contraindicated due to unacceptable toxicity. Severe dose adjustments or a palliative approach are recommended.
Correlation: Karnofsky vs ECOG / WHO
In modern practice, the ECOG (Zubrod) score is often used in parallel because it is faster to evaluate (from 0 to 5). The table below illustrates the standardized equivalence between these two global scales.
| Karnofsky Index | ECOG/WHO Equivalent | Global Category |
|---|---|---|
| 100% - 90% | ECOG 0 | Normal activity possible |
| 80% - 70% | ECOG 1 | Symptomatic but autonomous |
| 60% - 50% | ECOG 2 | In bed < 50% of the time (Unable to work) |
| 40% - 30% | ECOG 3 | In bed > 50% of the time (Strong dependency) |
| 20% - 0% | ECOG 4 - 5 | Confined to bed / Moribund |
References:
1. Karnofsky DA, Burchenal JH. The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod CM (Ed), Evaluation of Chemotherapeutic Agents. Columbia Univ Press, 1949.
[Columbia University]
2. Mor V, et al. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer. 1984.
[Wiley Online Library]
-
💡 Committed to scientific accuracy, if you notice any clinical or technical discrepancy, please let us know.